PARTICIPANTS

M. Absher, The University of Vermont, College of Medicine, Department of Hedical Microbiology, Given Building, Burlington, Vermont 05401, U.S.A.

A. Balazs, Institute of Experimental Medicine, Hungarian Academy of Sciences, Szigony u.43, P.O.B. 67, Budapest VIII, Hungary

F. Bartot, Faculty of Pharmacy, Charles University, 50027 Hradec Kr~love, Czechoslovakia

J. Z. Beer, Instytut badan jadrowych, Ul. Dorodna 16, 03-195, Harszawa, Poland

w. Beier, Institut fur Biophysik, Liebigstr. 27, 701 Leipzig, Deutsche Demokratische Republik

G. Butenko, Laboratory of Immunology, Institute of Gerontology MfS USSR, Vyshgorodskaya 67, 252655 Kiev, USSR

S. B. Carter, ICI Pharmaceuticals Division, Nareside Alderly Park, Macclesfield, Cheshire, England

P. Cervenka, Centre of Hygiene, Department of Virology, Partyzanske nam. 1, 72892 Ostrava, Czechoslovakia

F. Ciampor, Institute of Virology, Slovak Academy of Sciences, Mlynska Dolina 1, 809 39 Bratislava, Czechoslovakia

" J. Cinatl, Institute of Haematology and Blood Transfusion, U nemocnice 1, 120 00 Prague 2, Czechoslovakia

M. Christova, J.k. Krasno selo bl 10wh A, Sofia 80, Bulgaria

Y. Courtois, INSERM, Unite de recherches g~rontologiques, U.118, 29, Rue Hilhem, 75016 Paris, France

543

544 PARTICIPANTS

V. J. Cristofalo, The Wistar Institute, Thirty-sixth Street at Spruce, Philadelphia, Pa. 19104, U.S.A.

R. T. Dell'Orco, The Samuel Roberts noble Foundation, Ardmore, Oklahoma 73401, U.S.A.

A. J. Dewar, tiRC Brain Hetabolism Unit, University Department of Pharmacology, 1 George Square, Edinburgh EH8 9JZ, Scotland

Z. Deyl, Institute of Physiology, Czechoslovak Academy of Sciences, 1083 Bud~jovicka, 142 20 Prague 4, Czechoslovakia

L. Diamond, The Wistar Institute, Thirty-sixth Street at Spruce, Philadelphia, Pa. 19104, U.S.A.

~I. Dobiasova, Isotope Laboratories, Czechoslovak Academy of Sciences, Budejovicka 1083, 142 20 Prague 4, Czechoslovakia

V. Drastichova, Department of Biology and Pharmacology, Faculty Hospital, Peka~ska 53, Brno, Czechoslovakia

E. Faltova, Institute of Physiology, Czechoslovak Academy of Sciences, Budejovicka 1083, 142 20 Prague 4, Czechoslovakia

L. ri. Franks, Imperial Cancer Research Fund Laboratories, Depart­ment of Cellular Pathology, P. O. Box 123, Lincoln's Inn Fields, London, WC2A, 3PX, England

P. H. Gallop, Harvard Hedical School and School of Dental Hedicine, The Children's Hospital Hedical Center, Orthopedic Research Laboratories, 300 Longwood Avenue, Boston, t~ss. 02115, U.S.A.

E. Gutmann, Institute of Physiology, Czechoslovak Academy of Sciences, Budejovicka 1083, 142 20 Prague 4, Czechoslovakia

V. Hanzlikova, Institute of Physiology, Czechoslovak Academy of Sciences, Budejovicka 1083, 142 20 Prague 4, Czechoslovakia

R. J. Hay, Wright State University, Department of Biological Sciences, Dayton, Ohio 45431, U.S.A.

R. Helm, Institute of Physiology, Czechoslovak Academy of Sciences, Dudejovicka 1083, 142 20 Prague 4, Czechoslovakia

P. Hnevkovsky, Department of General Biology, tfedical Faculty, Charles University, Albertov 4, 12000 Prague 2, Czechoslovakia

PARTICIPAl'JTS 545

E. Hole~kov~, Institute of Physiology, Czechoslovak Academy of Sciences, Budejovicka 1083, 142 20 Prague 4, Czechoslovakia

K. Hor~kova, Chemical-Technological Faculty of the Slovak Poly­technical University, Janska 1., 83793 Bratislava, Czechoslovakia

J. Hurych, Institute of Hygiene and Epidemiology, C~ntre of Industrial Hygiene and Occupational Diseases, Srobarova 48, 10042 Prague 10, Czechoslovakia

-' M. Jelenska, Instytut badan jadrowych, Ul. Dorodna 16, 03-195

Warszawa, Poland

M. Juticov~, Institute of Physiology, Czechoslovak Academy of Sciences, Bud~jovick~ 1083, 142 20 Prague 4, Czechoslovakia

I. Kalbe, I. Med. Poliklinik/Charite/der Humboldtuniversitat, Hermann-Hatern Str. l3a, 104 Berlin, Deutsche Demokratische Republik

F. Kasten, Department of Anatomy, Louisiana State University Medical Center, 1100 Florida Avenue, New Orleans, Louisiana 70119, U.S.A.

L. Kazdova, Institute for Clinical and Experimental Hedicine, Budejovick~ 800, 14622 Prague 4, Czechoslovakia

D. L. Knook, Institute for Experimental Gerontology of the Organization for Health Research TNO, 151 Lange Kleiweg, Rijswijk, The Netherlands

A. Kocinger, I. Department of Medicine, 81200 Bratislava, Czechoslovakia

P. H. Leuenberger, University Eye Clinic, 22, Rue Alcide Jentzer, 1205 Geneva, Switzerland

G. Leutert, Anatomisches Institut, Karl-Marx-Universitat, Liebigstr. 13, 701 Leipzig, Deutsche Demokratische Republik

" H. Libikova, Institute of Virology, Slovak Academy of Sciences, Mlynska Dolina 1, 80939 Bratislava, Czechoslovakia

M. Macek, Institute for the Child Development Research, V uvalu 84, 15006 Prague 5, Czechoslovakia

546 PARTICIPANTS

A. Macieira-Coelho, ICIG, 14 & 16 Avenue Paul-Vaillant-Couturier, 94800 Villejuif, France

G. H. Hartin, University of Hashington, Seattle, Washington 98105, U.S.A.

S. Masaki, Koganei Branch, Fujisawa Pharmaceutical Co., Ltd., Nukuikita-machi 3-8-3, Koganei-shi, Tokyo, Japan

B. I1auesberger, Deutsche Akademie der Wissenschaften, Wilhelmstr. 4., 1136 Berlin, Deutsche Demokratische Republik

R. Maurer, Biological and Medical Research Division, Sandoz, Ltd., Ch-4002 Basel, Switzerland

J. Michl, Institute of Physiol~gy, Czechoslovak Academy of Sciences, Budtjovicka 1083, 142 20 Prague 4, Czechoslovakia

1. Horasca. Instituto di richerche farmacologiche "Hario Negri" Via Eritrea 62, 20157 Hilano, Italy

D. G. Murphy, Adult Development and Aging Branch, National Institute of Child Health and Human Development, NIH, Landow Building, C-703, Bethesda, Haryland 20014, U.S.A.

J. Najbrt, Institute for Clinical and Experimental Hedicine, Bud~jovicka 800, 14622 Prague 4, Czechoslovakia

vv... . . B. Ostadal, Inst~tute of Phys~ology, Czechoslovak Academy of

Sciences, Bud~jovicka 1083, 142 20 Prague 4, Czechoslovakia

A. C. H. Pieck, Laboratory for Chemical Cytology, University of Nijmwegen, The Netherlands

V. Pcissnerov~, Laboratory for Blood Research, Medical Faculty, Charles University, 12000 Prague 2, Czechoslovakia

A. Projan, Deutsche Akademie der Wissenschaften, Wilhelmstr. 4., 1136 Berlin, Deutsche Demokratische Republik

J. Reban, Department of Public Health, Palackeho 661, 37341 Hluboka nad Vltavou, Czechoslovakia

V ;v ;-D. Rezacova, Institute of Sera and Vaccines, W. Piecka 108, 10103

Prague 10, Czechoslovakia

A. Robinson, ICI Ltd., Pharmaceutical Division, Hareside, Alderley Park, Hacclesfield, Cheshire, England

PARTICIPANTS 547

P. Rossner, Institute of Hygiene and Epidemiology, Srobarova 48, 10042 Prague 10, Czechoslovakia

P. Rother, Anatomisches Institut, Karl-lfarx-Universitat, Liebigstr. 13, 701 Leipzig, Deutsche Demokratische Republik

W. Rotzsch, Abteilung fur klinische Chemie und Laboratoriums­diagnostik, Karl-Harx-Universitat, Liebigstr. 16, 701 Leipzig, Deutsche Demokratische Republik

C. Rowlatt, Imperial Cancer Research Fund Laboratories, Department of Cellular Pathology, P. O. Box Ho. 123, Lincoln's Inn fields, London HC2A 3PX, England

J. t!. Ryan, The IJistar Institute, Thirty-sixth Street at Spruce, Philadelphia, Pa. 19104, U.S.A.

F. T. Sielaff, 1. med. Klinik der Humboldtuniversitat, Hatern Str. l3a, 104 Berlin, Deutsche Demokratische Republik

J. Simons, Department of Radiation Genetics, State University of Leiden, Wassenaarseweg 62, Leiden, The Netherlands

J. Skrivanova, Department of General Biology, lfedical Faculty, Charles University, Albertov 4, 120 00 Prague 2, Czechoslovakia

H. Soukupova, Department of General Biology, l!edical Faculty, Charles University, Albertov 4, 120 00 Prague 2, Czechoslovakia

O. Sova, Department of Biochemistry, Institute of Experimental Biology, Slovak Academy of Sciences, Ul. vystavby, 04000 Ko~ice, Czechoslovakia

V. Spurna, Institute of Biophysics, Czechoslovak Academy of Sciences, Kralovopolska 135, 61200 Brno 12, Czechoslovakia

S. Stoklosowa, Instytut Zoologii, Uniwersitet Jagiellonski, Ul. Krupnicza 50, Krakow, Poland

" H. Sulcova, Eye Research Laboratory, Czechoslovak Academy of Sciences, U nemocnice 2, 120 00 Prague 2, Czechoslovakia

F. Tom~ik, University School of Veterinary Medicine, Palack~ho 1-3, 600 00 Brno, Czechoslovakia

M. Toporkova, Department of Biochemistry, Institute of Experimental Biology, Slovak Academy of Sciences, Ul. vystavby, 04000 Kosice, Czechoslovakia

548 PAl'SICIPANTS

o. Torok, Department of Biology, Semmelweis University of Medicine, T~zolt6 u. 58, Budapest IX, Hungary

A. Trojan, 1. Internal Department, Experimental Gerontological Center, Thomayer Hospital, Budejovicka 800, 146 29 Prague 4, Czechoslovakia

L. Ulehlova, Laboratory of Otolaryngology, Czechoslovak Academy of Sciences, U nemocnice 2, 120 00 Prague 2, Czechoslovakia

P. D. Hilson, Imperial Cancer Research Fund Laboratories, Depart­ment of Cellular Pathology, P. O. Box No. 123, Lincoln's Inn Fields, London I.JC2A, 3PX, England

SUBJECT INDEX

Abnormal proteins, 68, 69, 71, Amnion, 339 AQnion cells, 36 72, 79, 81

Acetysalicylic acid, 281, Acid deoxyribonuclease

(Acid DNase), 162

288-291 Amniotic fluid cells, 185, 187,

Acid hydrolases, 267, 268 Acid phosphatase, 56, 162, 207,

208, 265-268, 285 Acid RNAse II, 522, 526

189, 190, 339, 343, 347, 343 Amylase, 25, 28 Anticancer agents, 511, 515 Anti-inflammatory drugs, 293 Arrested cells, 41, 44 Arylsulphatase B, 162, 165 Ascitic cells, 529 Acinar cells, 24, 25, 28, 30

Actinomycin D, 471, 511, 513, Adaptability, 306

515 Ascitic fluid, 526

Adaptation of enzymes, 237 Adhesiveness, 148

Ascorbic acid, 331, 332, 335, 336 Aspirin, 291, 293 Asymmetric mitosis, 72, 74

Adipose tissue, 247-250, 252, Adrenals, 339

253 Auditory neuroepithelium, loss

Adriamycin, 513 Age, donor, 46, 515 Ageing (Aging), 257, 316, 329,

331, 332 cellular, 41 of connective tissues, 351 histological processes, 447 programmed, 2 randou damage, 2 rats, kidney weight of, 297,

298 as tHo-step process, 116

Alkaline phosphatase activity, 207, 208

Alkaline ru~ase II, 522, 524, 526 Alpha r;lobulin, growth promoting

activity, 137-141, 144, 145 Q-aminobutyric acid, 331 ~aminopropionitrile, 340

of, 257 Autolysis, postmortem, 190 Autophagic processes, 422 Autophagic vacuoles, 422 Autoradiography, 8, 79, 326

3H-thymidine, 193 Autoxidation, 268 Azetidine carboxylic acid, 70

Basal lamina, 216 Basement membrane, 424 B cells, 315, 316, 318-320 Betaine ~-hydroxylase, 331 Binucleated cells, 392-394 Biochemistry, 172, 177 Biomorphosis, sex-difference, Blindness, 281, 282 Bone cells, 373

549

442

550

Bone collagen, 371 Bone ground substance, 372 Bone marrow, 220, 339 Brain, 339 Calendar time, aging and, 44 Calf serum, 148 cAl1P, 79 Cancer cells, 511 Capillaries, ultrastructure, 379 Capillary wall, permeability,

development of, 379 Cardiac masses, 393 Cardiac muscle, rat, 379 Cardiac myoarchitecture,

development of, 375 Carnitine synthetase, 331 Cartilage, 23 Catalase, 265, 268 Cathepsin D, 162 Cell

adhesiveness, 148 analysis, 502 cycle, 147, 497, 498 death, 151 differentiation, 147 disturbances, 505 division, 58, 393, 394

patterns, 91, 100, 101, 103 potential, 47

fusion, 503 genealogies, 91, 92, 94, 99,

100, 103 kinetics, 51 lines, hyperplastoid, 67 loss, 147 nitrogen, increase of, 344 permeability, 57 proliferation, 247

ascites, 529 protein, 344 size, 107, 111, 119, 120

distribution, 108, 113, 120 surface alterations, 147, 148 surface receptors, 78 transformation, 147 volume, 55, 111, 113, 116,

221

SUBJECT INDEX

Cells (see individual) Cellular aging, 41 Cellular proliferation,

hyperplastic, 67 CF-l cells, 43, 44 Chemotherapeutic agents, 513, 515 Chick embryo cells, 469, 481-484 Chick embryo fibroblast, 148 Chick embryo myoblasts, 144 Chick embryo skin slices, 188, 190 Children (tissues of), 339, 341,

345 Chinese hamster cells, 499 Cholesterol, distribution of, 460

esterified, 461 free, 461

Chromatin, 123, 124, 126, 128, 131 template activity, 124, 126,

128, 131 Chromosome analysis, 198, 513, 518 Chromosome, C-9 subterminal

constriction, 198 Chromosomes, 518

anomalies of C group, 198 Ciliary muscle, 441 Clone

analysis of, 26 attenuation of, 68, 74 evolution of, 198 selection of, 70, 74 senescence of, 67, 68 slowly growing, 498, 499, 502

Cloning, 69 CHP (cytidine monophosphate), 266 Cold acclimation, 306 Collagen, 23, 331, 332, 335, 351

associated with cell layer, 347 cxchains, 343 concentrations in kidneys

and liver of fully-fed animals, 365

insoluble, 339 maturation in vitro, 345 metabolism, prenatal study, 347 soluble, 339 synthesis, 197, 190, 339-344

Collagenase, 156

SUBJECT INDEX

Colonial aggregates, 23, 28, 30 Combined stressors, 313 Connective tissue, proliferation

of, 443 Contact-inhibition, 147 Contractile activity, 391 Contractile rates, 393 Contractile tissue, 392 Contracting cells, 391 Contraction, 392, 431 Cortisone, 58 Creatine phosphate, 188, 190 Creatinephosphokinase (CPK) , 185,

188 embryonal, foetal and

children, 185, 187, 188 Cross-striated fibers, 144 Crypt epithelium, 215 Crystal-like arrangement of

tetrads, 481, 483 Culture-derived tumours, 526 Culture time, and aging, 41 Cyclic AMP, 79 Cytidine monophosphate (CHP) , 266 Cytochemistry, 172, 175, 266, 267 Cytochrome oxidase, 171, 172, 175,

179 Cytokinesis, 393 Cytopathic effect (CPE), 470 Cytoplasm, 344 Cytoplasmic volume (of hepato­

cytes), 159

Denervation, 431 Dense bodies, 265, 267 Deoxyribonucleic acid (DNA), 51

content, 306 in L cells, 139 polymerase, 394 synthesis, 10, 107, 113, 116,

118-120, 247-253, 393 serum stimulation of, 13

Diaminobenzidine 3,3' (DAB), 266, 268

Diaphram, 339

551

"Differential attachment technique", 390

Differentiated cells, 393 Differentiating system, 72 Differentiation, 74, 76, 82, 431

genetically programmed, 74 Diploid cells, 207 DNA (deoxyribonucleic acid), 51 Donor age, 46, 515 Dopamine p-hydroxy1ase, 331 Doubling time, 56 Drosophila melanogaster, 207 Drosophila strains, long-lived

white, 207

Eagle's medium, 148 EB virus, 198 Ehrlich ascites tumours, 523 Electron microscopy, 529 Embryogenesis, 391 Embryos, tissues of, 339, 341, 345

(also see individual cell lines)

Endoplasmic reticulum (ER), 265, 267 rough, 344

Endothelial cells, 155, 157-159, 390, 391

Endothelial-like cells, 515 Enterocytes, 235 Enzyme activities, in mouse

ascites cells, 522 Enzyme-histochemical investi­

gations, 237 Enzymes, adaption of, 237 Epithelial cells, clonally­

derived, 23, 26, 27 Error

accumulation, 118 catastrophy, 119 of collagen metabolism, 347 hypothesis, 241 in proteins, 119 in protein synthesis, 61, 344

Erythrocytes, volumes of, 221

552

Exocrine cells, 24 Experimental tumors, 511 Explanted tissue, latent period

of, 515 Eye, 265, 266, 268, 339

Fat-storing cells, 157 Fatty degeneration, 451, 455 Fetal strains, 515 Fibrillar rolP, 482 Fibroblastoid morphology, 186 Fibroblasts, 72-79, 190, 339 Fine filaments, 343 Flow microfluorometry, 42 Foetal blood, 339 Foetal cultures (see also indiv­

idual cell lines), 187 Foetuses, tissue of (see also

individual), 339, 341, 345 Food restriction, 359

Gl phase, 116, 502 Gl block, 499 G2 phase, 116, 499, 505

duration, 502, 505 G2 block, 502, 505 t1- galactosidase, 162, 165,

287 Ganglion cell, 267 Genetically programmed

(differentiation), 74 Genetic stability, 198

285,

GERL (see also Golgi, Endoplasmic reticulum, lysosomes), 139, 265, 267

Gingiva, 339, 340 Globulin, alpha growth promoting

activity, 137-141, 144, 145 Glucosamine, 148

labeling of cell surface, 152

Glucose-6-phosphate dehydrogenase, 69-71

SUBJECT IlIDEX

8- glucuronidase, 285, 287, 291 Glutamine synthetase, 16 Glycogen, 454, 458, 531

granules, 422 Glycoproteins, 151 Golgi apparatus, 267, 392 Golgi-endoplasmic reticulum

lysosome, 265, 267, 139 Gomori-positive cells, 323 GPAG (see also growth promoting

alpha globulin) Granular RNP, 482, 483 Growth curves, 111 Growth kinetics, 515 Growth phase, active, 186, 340 Growth process, "abortive

regenerative", 422 Growth promoting alpha-globulin

(GPAG), 137-141, 144, 145 Growth span, 515 Guinea pig, 257

Heat labile enzyme, 70, 71 Heart, 339 HeLa cells, 80 Hepatocytes, 162, 165, 235

cytoplasmic volume of, 159 Heritable cell cycle disturb­

ances, 505 Heritable damage, 497, 502, 505 Herpes simplex virus, 481-483

type 1, 470, 473 Heterokaryons, 69, 79 Hexosaminidase, 285, 287, 291 Histiocytes, 78 Histone, 123

acetylation, 123, 124, 126, 131 Hormone, 59 HSV, 481-483

HSV 1 infection, 473 Human amnion cell, 36 Human diploid cells, 7, 41, 185 Human fibroblasts, 51, 515 Hyaluronidase, 150, 156 Hydrocortisone, 7-22, 58

SUBJECT INDEX

Hydroxylation, 331, 335, 336 Hydroxyproline, 339 Hyperplastic cellular prolifera­

tion, 67 Hyperplastoid cell lines, 67 Hypertrophy, 119, 393, 394

Immune response, 315 to viral infections, 469

Immunofluorescence, 471 Influenza virus, 483 Intercalated discs, 391 Intercellular space, 344 Interdivision time, 91, 94, 100,

101, 103 Interferon, 470, 473, 476, 482

back effect, 471, 473, 476 depression of, 483 derepression of, 476

Intermitotic cells, 235 Interstitial tissue, 393 Intracellular fibrills, 347 Intranucleolar chromatin, 482,

483 Iodine, 125, 323 Iodine incorporation, 326 Ionizing radiation, 497, 505 Isolated stressors, 313

Jejunum, 215

Karyotype, leucocyte cultures, 193

a-keto-glutarate, 331 Kidney, 339

growth, 297 hyperplasia, 306 number of cells, 297 weight, 2, 297, 298, 306

Kupffer cells, 155, 157-159, 162 phagocytic activity of, 157

L5l78Y cells, mouse lymphoma, 521, 523, 526

553

L5l78Y-S cells, murine lymphoma, 497

Labelling index, 14, 502 Lactic acid, l8G Larvae, 208 Latent period, of explanted

tissue, 515 Late recovery, 502, 505 Lecithin-lysolecithin conver-

sion, 459 Leukaemic cells, 529 Leukocyte cultures, long-term, 193 Lifespan, 40, 58, 156

finite, in vitro, 1, 41, 219 genetically determined, 1 programmed, 2 switching-off process, 3

Lipid droplets, in muscle, 424 Lipid metabolism, 265, 268 Lipofuscin, 158, 268

granules, 265, 267, 424 Lipoprotein spectrum, 460 Lipovnik virus, 473 Liver, 339

rat, 155, 156 Liver cells

parenchymal, 155-159, 162, 165, 166

non-parenchymal, 155-158, 162, 165, 166

Lobation of the nucleus, 481 Long-lived white Drosophila

strains, 207 Lung cultures, 185 Lymphoblastoid cells, 193 Lymphoid cells, 198 Lysolecithin, as a potential

transport vehicle for cholesterol, 459

Lysosomal enzymes, 155, 156, 162, 165, 207, 288 activity, 156, 158, 162, 165 release, 287

Lysosomal structures, 157-159 Lysosome-like bodies, 120

554

Lysosomes, 79, 115, 265, 268, 281, 285, 287, 291 in liver, 155, 156, 158,

162, 165 secondary, 159, 481-483

Macrophage-like cell, 102 Macrophages, 69, 78, 79 Malate dehydrogenase, 171, 172,

175, 179 Mammary tissue, mouse, 118 Marfan Syndrome, 340, 345 Matrix, 171-173, 175, 178, 179 Medium (see individual) Medium, from aged cultures, 476 Medium EPL, 185, 339 Medium, low serum, 42 Melanin, 282 N-methylglucamine, 291 6-methylmercapto-purine riboside,

515 Mice, 30-month old, 171, 174

CBA-Rij, 220 C57Bl, 215

Microfibrils, 79 Microfluorometry, flow, 42 Microperoxisomes, 265 Migration patterns, 91, 100 "Mini hearts", 389, 392, 394 Mitochondria, 115, 120, 171-179,

216 enlarged, 171-173, 175, 178

Mitochondrial degradation, in muscle, 424

Mitochondrial fractions, 171, 175 Mytomycin C, 113, 119 Mitosis, 389, 394, 518

asymmetric, 72, 74 Mitotically active cells, 107 Mitotic cells, Ill, 113, 119 Mitotic cycle, 497 Mitotic division, 247, 252 Mitotic transformed cells, 119 Mitotic WI38 cells, 120 Mixed viral infections, 473 Monolayer cells, 11, 113, 119 Horphological analysis of

chromosomes, 518

SUBJECT INDEX

Morphometrical cytology, 159 Morphometric changes (in

lysosomes), 156 Morphometric studies, 159 Mosaic 45 XX C-/46 XX, 199 Motor endplates, 424 Mouse kidney, 521 Mouse liver, 521 Mouse lymphoma, L5l78Y cells,

521, 523, 526 Mouse mammary tissue, 118 Mouse pancreas, 521 Mucopolysaccharides, 151 Multilamellar bodies, 481, 483 Murine lymphoma L5l78Y-S cells,

497 Muscle, 339, 476

connective tissue relation, 441

cultures, 185 fast and slow, 431 fibre, histochemical pattern,

431 grafts, 434 senile, 421 skeletal, 421

Mycoplasma, 8, 108 Myoblasts, 393 Myofibrils, 390, 391, 394

loss of, 422 Myofilaments, 391

disorganization and disintegration, 422

Myopodial extensions, 392 Myopodial processes, 392 Myotubes, 144

Neoplastic proliferation, 67, 82 Neoplastoid cell lines, 67, 77

78, 80-82 Nephrectomy, unilateral, 297, 306 Neuroepithelium, auditory loss

of, 257 Neuromuscular disturbance,

422 Neuromuscular junction, 424

SUBJECT INDEX

Nitrogen mustard, 513 Non-cycling cells, 116, 502 Nondisjunction, 77 Nondividing cells, 113, 120 Nondividing subpopulations, 107 Nonlinear age dependence, 441 Nonmitotic state, 41 Nuclear fragmentation, 422 Nuclear monolayers, 124, 128, 131 Nucleus, lobation of, 481

Ontogenetic development, 247 Orgel hypothesis, 67, 68, 344 Oxidation, 118

Pacemaker, 389 cells, 4

Pancreatic acinar cells, 30, 36 Pancreatic cell aggregates, 28 Pancreatic ~pithelial cells, 30 Pancreozymin, 25 Pentads, 422 Perfused livers, 171, 174, 175 Pericardium, 339

cultures, 185, 187, 189 Perinuclear chromatin, 481, 483 Periosteum, 511 Peritoneal wash, 526 Peritoneum, 339 Permeability of the capillary

wall, development of, 379 Peroxidase, 268

activity of, 157 Peroxides, 268 Phagocytic activity (of Kupffer

cells), 157 Phagolysosomal system, 265, 266,

268 Phase III, 108, 119 pH me?surements, 187, 190 32P04~ binding of, 138

relative incorporation of, 144

555

Phospholipase A, 460 Phospholipids, 454, 455, 458 Pigment epithelium, 265, 267,

268 Pinocytosis, 139

of GPAG, 140 Pituitary polypeptides, 16 Plasma membrane, 156 Pleura, 339 Polykaryocyte, 470, 473 Polyploid cells, 159, 165 Polyploidization, 394 Population distribution, 42 Population doublings, 41, 44 Postnatal phase of development,

343 Postmortem autolysis, 190 Post-replicative cells, 69, 71 Postsynaptic functional folds,

424 Praenatal phase of development,

343 Prenatal period, 190 Primary synaptic clefts, 424 Proliferating pool, 16 Proliferation, of connective

tissue, 443 Proliferation, of the sarco­

plasmic system, 422 Proliferation of the tubular

T-system, 422 Proliferative state, 44 Prolyl hydroxylase, 331, 335 Pronase, 150, 157, 158 Protein, 54

cellular, 43 concentration, increase of,

340 content, 165 proximo-distal transport

of, 424 synthesis, 113

Pseudogranula, 197 Pseudorabies virus, 470 Pupae, 208

556

Quantitative studies, 171

Radiation-induced heritable lesions, 502, 505

Radioautography, 326 Rat cardiac muscle, 379 "Redifferentiation", 391 Regeneration, 431 Reinervation, 431 Replicate DUA, 116, 119 Repressors, 476 Reproduction, 481-483 Residual bodies, 424 Respiration, 156 Retina, 265, 281 Retinal

degeneration, 281, 282, 285 dystrophy, 281 RNA and DUA, 283-285, 291,

293 Retinitis pigmentosa, 281 Retinol, 281, 282, 285, 287,

288, 291 Retinopathy, 265, 268 Rib, 339 Ribonuclease, 521, 526 Ribosomal mTA, 51 Ribosomal structures, crystal-

like, 483 RNA, 51, 123, 124, 126, 128, 131 P~ase I, 521, 523, 526 RNase II, 521 RtTA synthesis, 113, 119 Rosette techniques, 69 Roth's method, 148 Rough endoplasmic reticulum, 344

Sarcolemma, 422 l-sarcolysine, 513 Sarcomere integrity, loss of, 424 Sarcomeres, 391, 392 Sarcoplasmic system, prolifera-

tion of, 422 Sarcosomes, 391

SUBJECT INDEX

Saturation density, 56, 111 "Scavenger" enzyme systems, 81 Secondary lysosomes, 159, 481,

483 Secretogogue pancreozymin, 30 Selective inhibition, 483 Senescence in vitro, 51 Senile motor-units, 431 Senile muscle, 421

grafts, 434 Sensitivity of normal cells, 515 Sepharose 6B, 148 Serum stimulation of DnA

synthesis, 13 Sex-difference biomorphosis, 442 Sinusoidal cells, 159 Skeletal muscles, 421 Skin, 476

cultures, 185, 187 fibroblast cultures, 67, 70,

72, 78 Smooth membrane fractions, 150 Solid tumors, 339 Solubility data, 356 Spinal cord, 339 Spindle-shaped cells, 513 Spleen, 339

cells, 220, 221 cultures, 185, 187, 189

Spleen cells proliferative capacity, 227 serial transplantation, 228 size distribution, 228

Stable phenotypic changes, 503 Stem cells, 68, 72, 74, 215 Stochastic process, 74 Streaming of the Z-band, 422 Stressing agents, 306 Stromatic cells, 511 Subterminal constriction, C-9

chromosome, 198 Sucrose gradient, 59 SV40 transformed fibroblast, 80 SV40 virus, 107, 119 Swelling of the mitochondria,

481, 483 Synaptic clefts, primary, 424 Synaptic vesicles, 424

SUBJECT IHDEX

Synchronized networks, 394

T cells, 315, 316, 318-320 3T3 cells, 16 Terminal axons 424 Terminal differentiation, 68, 71,

74,77,78 Tetrads, 483

crystal-like structure of, 481, 483

Thiaminepyrophosphate (TPP) , 266 3H thymidine, 148

binding of, 138 Thymus, 339

culture, 185, 187, 189 tissue cultures, 323

Tick-borne encephalitis virus, 470, 471

Time-lapse cinemicrophotography, 91, 100

Tissue, 521 specific products, 23

Tissues (see individual) Transformed WI38, 107, 108, Ill,

115 Transplantation, 220 Trenimon, 513 Triads complexes, 422 Trypan blue exclusion, 156, 157 Trypsin, 148 TSn, 323 T-system, tubular proliferation

of, 422 Tumours, culture-derived, 526

Umbilical cord, 339 cultures from, 185, 187, 189

Unilateral nephrectomy, 297, 306 3H-uridine, binding of, 138

Vacuoles, 530

557

Vascular bed, terminal evolution of, 375

Veinous wall, 451, 454, 455 Ventricle, 390 Villus epithelium, 215 Viral antigen, 473 Virus (see individual) Virus infection, 481-483 Virus reproduction, 470 Visual pigment, 281, 285 Vitality, 240 Vitamin A alcohol, 281 Volume fractions, 159

Western equine encephalo­myelitis virus, 470, 473

~H26 cells, 8 WI38 cells, 8, 44, 79, 107, 115

119, 120, 329, 332, 335 HI38 VA13 cells, 11, 107 ULH cells, 44 Hound healing, 67, 74

Z-band, streaming of, 422 Z-line, 391, 393, 422 Zymogen droplets, 28